The company pointed to "recent market challenges" and "share price decline" as reasons for Lars Fruergaard Jørgensen's ...

In an abrupt and surprising twist, the CEO of Ozempic-maker Novo Nordisk has been ousted from his position as the head of the ...

Novo’s shares have plunged since hitting a record-high in June last year as competition, particularly from Eli Lilly, makes inroads into its market share and as its pipeline of new drugs has ...

The Royal College of GPs’ weight loss expert has sounded a warning bell for users of popular drugs Ozempic, Mounjaro and ...

Ozempic-maker Novo Nordisk on Friday ousted its CEO Lars Fruergaard Jorgensen over concerns the company is losing its ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

Danish drugmaker Novo Nordisk, known for its blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, said Friday ...

New research has shown that Ozempic can cause taste changes in people taking it, even going so far as to make some hate the ...

A recent study showed that well-known diabetes and weight loss drugs such as Ozempic and Wegovy do not raise the risk of ...

There are plenty of people taking Ozempic to lose weight, but Doctor Giles Yeo has explained the main problem people have ...

Medically reviewed by Femi Aremu, PharmD Ozempic and Wegovy are both glucagon-like peptide-1 (GLP-1) receptor agonists and contain the active ingredient semaglutide. They share many similarities, and ...

Novo Nordisk, the company that makes the weight loss drugs Ozempic and Wegovy, is abruptly ousting its chief executive, Lars Fruergaard Jørgensen, over concerns the firm is losing ground in the ...